Caliber Imaging & Diagnostics

Caliber Imaging & Diagnostics

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

Caliber I.D. is a privately held medical technology company based in Rochester, NY, founded in 2008. It has developed and commercialized a proprietary platform of in vivo confocal microscopy devices, most notably the VivaScope systems, which enable non-invasive, real-time visualization of cellular morphology. The technology serves as a powerful adjunct to biopsy, aiding in the diagnosis of skin cancers like melanoma and improving surgical margin assessment. The company operates in the diagnostics and medical devices sectors, generating revenue through the sale of its imaging systems and related software and services.

DermatologyOncology

Technology Platform

In vivo reflectance confocal microscopy (RCM) for non-invasive, real-time cellular-level imaging of skin and epithelial tissues.

Funding History

2
Total raised:$25M
Series B$15M
Series A$10M

Opportunities

The global rise in skin cancer incidence and a strong clinical need for non-invasive diagnostic tools create a significant market.
Expansion into new clinical areas beyond dermatology (e.g., other epithelial cancers) and integration of AI for image analysis represent major growth vectors.

Risk Factors

Commercial adoption is hindered by challenges in securing consistent insurance reimbursement and changing clinical workflows.
The company faces competition from other imaging modalities and bears the financial and execution risks common to small, private medical device firms.

Competitive Landscape

Caliber I.D. competes with other non-invasive skin imaging devices like optical coherence tomography (OCT) systems and high-frequency ultrasound. It also competes indirectly with the standard of care—visual inspection and biopsy—and digital dermoscopy platforms. Its primary competitive advantage is the cellular-level resolution of confocal microscopy.